文献速递免疫规划传染病防控与疫情报告环境卫生

伊朗甲型肝炎病毒免疫力的全国人群血清流行率研究

Immunity to Hepatitis-A virus: A nationwide population-based seroprevalence study from Iran.
PubMed 文献 · Vaccine · 2020-09-09

该研究在伊朗12个省份采用多阶段整群随机抽样纳入5419名参与者,通过问卷和采血检测HAV-IgG,发现总体血清阳性率为66.5%,15岁以下儿童免疫率41.1%,约30岁成人免疫率82.6%,免疫中点年龄为21岁,结论认为伊朗属HAV低流行国家,仅推荐高危人群接种疫苗。

要点

  • 伊朗总体HAV-IgG血清阳性率为66.5%,免疫中点年龄为21岁。
  • 15岁以下儿童免疫率41.1%,约30岁成人免疫率82.6%。
  • 仅推荐慢性肝病、凝血病患者、高流行区旅行者及男同性恋者等高危人群接种HAV疫苗。

核心结论

  • 伊朗属于甲型肝炎病毒低流行国家,仅推荐高危人群接种HAV疫苗。

研究设计与样本

  • 基于人群的血清流行率研究,通过多阶段整群随机抽样从伊朗12个省份的57个城市和120个农村地区选取5419名参与者,进行问卷访谈并采集3 cc血样检测HAV-IgG。

主要发现

  • 参与者平均年龄26.4±16岁,范围1至94岁,男女比1.02。
  • 总体3603人(66.5%)HAV-IgG血清阳性。
  • 15岁以下儿童中41.1%免疫,约30岁成人中82.6%免疫,人群免疫中点年龄为21岁。
  • 边境居民、安全饮水或卫生厕所可及性较低者、低社会经济地位者及大家庭成员血清阳性的可能性最高。

关键数值与推荐

  • 推荐高危人群接种HAV疫苗,包括慢性肝病患者、凝血病患者、前往高流行区的旅行者及男同性恋者。
  • 建议建立国家HAV监测系统,关注HAV暴发,实施减害策略,改善经济指标、卫生条件及欠发达地区安全饮水可及性。

临床怎么用

  • 在伊朗等低流行区,应针对慢性肝病、凝血病、高流行区旅行者及男同性恋者等高危人群接种HAV疫苗,而非普遍接种。
  • 需建立国家HAV监测系统并关注暴发风险,同时改善欠发达地区的卫生设施和安全饮水。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mortality rate of acute Hepatitis A increases from 0.1% in the children to 1.2%, in the adults. Hepatitis A is efficiently prevented by HAV-vaccine, but the strategy for distributing this vaccine among countries is dependent on their level of immunity to HAV. This study aimed to detect the level of immunity to HAV in Iran. METHODS: In this population-based seroprevalence study, 5419 participants from 12 of provinces of Iran, including 57 urban and 120 rural areas were chosen through a multi-stage cluster random sampling. Participants were interviewed by filling checklists and 3 cc of blood sample was obtained from each of them. IBM SPSS statistics V.21 software was used for univariable and multivariable analysis of data. RESULTS: Mean of age of Interviewees was 26.4 ± 16 years, ranging from 1 to 94 years with a male to female ratio 1.02. Overall, 3603 (66.5%) of subjects were seropositive for HAV-IgG. Among the age groups, 41.1% of children by the age 15 years and 82.6% of adults around 30 years old were immune to HAV. The Mid-point age of population immunity was 21 years. Residents of the borders of the country, people who had less access to the safe water or sanitary toilet, individuals with low socioeconomic status and persons who were a member of dense families had the most probability of seropositivity. CONCLUSIONS: This study showed that Iran is among HAV low endemic countries and vaccination against HAV is recommended only in the high-risk population, including patients with chronic liver diseases, patients with coagulopathy, travelers to the high endemic areas, and homosexuals. Establishment of national HAV surveillance system, concerning of health system about the occurrence of the HAV outbreaks, implementation of harm reduction strategies, improving economic indices and sanitation and access to the safe water in the deprived regions is recommended.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lankarani KB, Honarvar B, Molavi Vardanjani H, et al. Immunity to Hepatitis-A virus: A nationwide population-based seroprevalence study from Iran. Vaccine. 2020. PMID: 32917416. doi:10.1016/j.vaccine.2020.08.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。